New antibody drug takes on hard-to-treat ovarian cancer
NCT ID NCT06515613
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 30 times
Summary
This early-phase study tests a new drug called CTIM-76 in people with ovarian, testicular, or endometrial cancer that has come back or stopped responding to standard treatments. The drug is designed to help the body's immune cells find and attack cancer cells that have a specific marker (CLDN6). The main goals are to check safety and see if the drug can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Duke Cancer Institute
RECRUITINGDurham, North Carolina, 27710, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fox Chase Cancer Center
WITHDRAWNPhiladelphia, Pennsylvania, 19111, United States
-
Gabrail Cancer Center
WITHDRAWNCanton, Ohio, 44718, United States
-
John Theurer Cancer Center
TERMINATEDHackensack, New Jersey, 07601, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10021, United States
Contact Email: •••••@•••••
-
Precision NextGen Oncology & Research Center
WITHDRAWNBeverly Hills, California, 90212, United States
-
Providence Cancer Institute of Oregon
RECRUITINGPortland, Oregon, 97213, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
SCRI at Denver Health
RECRUITINGDenver, Colorado, 80218, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
SCRI at Mary Crowley
RECRUITINGDallas, Texas, 75230, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University College London Hospital
RECRUITINGLondon, United Kingdom
Contact Email: •••••@•••••
-
University of Arkansas Winthrop P. Rockefeller Cancer Institute
RECRUITINGLittle Rock, Arkansas, 72205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Vanderbilt-Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Women & Infants Hospital of Rhode Island
RECRUITINGProvidence, Rhode Island, 02905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.